Research Report explore the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016 "The Report Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. MarketResearchReports.biz" GlobalData's clinical trial report, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for inprogress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/761824 Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to buy
Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Report Guidance 7 Clinical Trials by Region 8 Clinical Trials and Average Enrollment by Country 9 Top Five Countries Contributing to Clinical Trials in AsiaPacific 11 Top Five Countries Contributing to Clinical Trials in Europe 12 Top Countries Contributing to Clinical Trials in North America 13 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14 Top Five Countries Contributing to Clinical Trials in Central and South America 15 Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 16 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 19 Clinical Trials by Phase in E7 Countries 20 Clinical Trials in E7 Countries by Trial Status 21 Clinical Trials by Phase 22 In Progress Trials by Phase 23 Clinical Trials by Trial Status 24 Clinical Trials by End Point Status 25 Subjects Recruited Over a Period of Time 26 Clinical Trials by Sponsor Type 27 Prominent Sponsors 28 Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 29 Prominent Drugs 31 Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 32 Jun 14, 2016: Celator Pharmaceuticals Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in HighRisk Acute Myeloid Leukemia 32 Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGNCD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association 33 Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant AntiTumor
Activity of its Lead Drug Candidate SY1425 at 21st Congress of the European Hematology Association 34 Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant AntiTumor Activity of its Lead Drug Candidate SY1365 at 21st Congress of the European Hematology Association 34 Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 35 About us MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact Mr. Nachiket State Tower 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +15186212074 Website: http://www.marketresearchreports.biz/ E: sales@marketresearchreports.biz